Octreotide vs Lanreotide
A long-acting somatostatin analog used to suppress GH and other hormones. A depot somatostatin analog, similar in action to octreotide. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Octreotide | Lanreotide | |
|---|---|---|
| Also known as | Sandostatin | Somatuline |
| Type | Analog | Analog |
| Evidence | Established | Established |
| Family | Growth & repair | Growth & repair |
| Class | Somatostatin analog (cyclic octapeptide) | Somatostatin analog (cyclic octapeptide) |
| Receptor | Somatostatin receptors (SSTR2 and SSTR5 preferential) | Somatostatin receptors (SSTR2 and SSTR5 preferential) |
| Molecular weight | ~1,019.2 Da | ~1,096.3 Da |
| Half-life | depot-dominant (autogel acts over weeks) | |
| Based on | Somatostatin | Somatostatin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Octreotide and Lanreotide?
- Octreotide is an engineered analog based on Somatostatin; Lanreotide is an engineered analog based on Somatostatin. Octreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential); Lanreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential).
- How do the half-lives of Octreotide and Lanreotide compare?
- The reported circulating half-life of Octreotide is ~1.5 h (subcutaneous; LAR depot ~monthly); Lanreotide is depot-dominant (autogel acts over weeks). These are reference values for the native or representative form — educational only, not dosing advice.
- Is Octreotide the same as Sandostatin?
- Sandostatin is a brand name of Octreotide. This comparison describes the molecules, not branded products.
Prefer the other order? Lanreotide vs Octreotide. Or open the interactive comparison tool to add more molecules.